首页 > 最新文献

Personalized Medicine Universe最新文献

英文 中文
Precision medicine, Universal Health Coverage (UHC) and intestinal microflora as a new platform for health promotion 精准医疗、全民健康覆盖和肠道菌群作为健康促进的新平台
Pub Date : 2019-07-01 DOI: 10.1016/j.pmu.2019.04.003
Hideyuki Akaza
{"title":"Precision medicine, Universal Health Coverage (UHC) and intestinal microflora as a new platform for health promotion","authors":"Hideyuki Akaza","doi":"10.1016/j.pmu.2019.04.003","DOIUrl":"10.1016/j.pmu.2019.04.003","url":null,"abstract":"","PeriodicalId":101009,"journal":{"name":"Personalized Medicine Universe","volume":"8 ","pages":"Pages 1-2"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pmu.2019.04.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76742534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
A case of refractory serum sodium disorders with severe multiple trauma 难治性血清钠紊乱伴严重多发创伤1例
Pub Date : 2019-07-01 DOI: 10.1016/j.pmu.2019.06.001
Kasumi Satoh, Tomoki Furuya, Manabu Okuyama, Hajime Nakae

A 40-year-old man was admitted to the hospital with multiple injuries, including head injury and his laboratory results were significant for sodium abnormalities. Initially, hypernatremia was from increased sodium intake. Subsequently, hyponatremia developed that was unresponsive to sodium supplementation. Syndrome of inappropriate antidiuretic hormone secretion or cerebral salt wasting syndrome was suspected. Additional tests suggested post-traumatic hypopituitarism was responsible for the hyponatremia. Corticosteroid were given which normalized the serum sodium level, but the urine volume increased. Masked diabetes insipidus was suspected and desmopressin was given, stabilizing the serum sodium level. Recognizing the factors that cause sodium abnormalities in trauma patients can help lead to the correct diagnosis.

一名40岁男子因多处受伤入院,包括头部受伤,他的实验室结果显示钠异常。最初,高钠血症是由钠摄入量增加引起的。随后出现了对钠补充无反应的低钠血症。怀疑有抗利尿激素分泌不当综合征或脑盐消耗综合征。额外的测试表明创伤后垂体功能低下是低钠血症的原因。给予皮质类固醇使血清钠水平正常化,但尿量增加。怀疑隐匿性尿崩症,给予去氨加压素,稳定血清钠水平。认识到导致创伤患者钠异常的因素有助于正确诊断。
{"title":"A case of refractory serum sodium disorders with severe multiple trauma","authors":"Kasumi Satoh,&nbsp;Tomoki Furuya,&nbsp;Manabu Okuyama,&nbsp;Hajime Nakae","doi":"10.1016/j.pmu.2019.06.001","DOIUrl":"10.1016/j.pmu.2019.06.001","url":null,"abstract":"<div><p><span><span><span>A 40-year-old man was admitted to the hospital with multiple injuries<span>, including head injury and his laboratory results were significant for sodium abnormalities. Initially, </span></span>hypernatremia<span> was from increased sodium intake. Subsequently, </span></span>hyponatremia developed that was unresponsive to sodium supplementation. </span>Syndrome of inappropriate antidiuretic hormone secretion<span><span> or cerebral salt wasting syndrome<span> was suspected. Additional tests suggested post-traumatic hypopituitarism was responsible for the hyponatremia. Corticosteroid were given which normalized the serum sodium level, but the urine volume increased. Masked </span></span>diabetes insipidus was suspected and desmopressin was given, stabilizing the serum sodium level. Recognizing the factors that cause sodium abnormalities in trauma patients can help lead to the correct diagnosis.</span></p></div>","PeriodicalId":101009,"journal":{"name":"Personalized Medicine Universe","volume":"8 ","pages":"Pages 38-40"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pmu.2019.06.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77102807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Lentiviral vector-mediated gene transfer combined with cisplatin enhances tumor suppression in human bladder cancer cell lines 慢病毒载体介导的基因转移联合顺铂增强人膀胱癌细胞系的抑瘤作用
Pub Date : 2019-07-01 DOI: 10.1016/j.pmu.2019.06.002
Misa Ichikawa , Wataru Matsunaga , Takahiro Ishikawa , Akinobu Gotoh

Purpose

Non-muscle invasive bladder cancer (NMIBC) shows high rates of recurrence and frequently progresses to more advanced stages, such as muscle invasive bladder cancer (MIBC). Repetition of treatment and recurrence are serious burdens and cause severe reduction in the quality of life (QOL) of patients. Thus, a novel therapeutic strategy without high burdens on the patients is an urgent requirement. Consequently, we evaluated tumor growth inhibition in bladder cancer cell lines using a combination of cisplatin (CDDP), one of the prevailing anticancer drugs to treat bladder cancer, and lentiviral vector-mediated gene transfer, where the vector is known to have minimal cytotoxicity.

Methods

Lentiviral vector with tumor suppressor genes including p53, p16, and phosphatase and tensin homology (PTEN) were infected to human bladder cancer cell lines, UMUC3 and T24, followed by CDDP treatment.

Results

The transduction of the p53, p16, or PTEN gene was equivalent to the antitumor efficacy of CDDP against bladder cancer cells. Furthermore, lentiviral vector-mediated transduction of tumor suppressive genes in combination with CDDP showed superior antitumor effects relative to individual treatment strategies with the vector or CDDP alone.

Conclusion

Lentiviral vector-mediated gene transduction is a promising alternative to the existing therapy in treating bladder cancer. The current protocol of CDDP-based chemotherapy may be replaced in the future. Moreover, the combination of gene therapy and chemotherapy may be an effective treatment for bladder cancer.

目的:非肌肉浸润性膀胱癌(NMIBC)具有高复发率,并经常发展到更晚期,如肌肉浸润性膀胱癌(MIBC)。重复治疗和复发是严重的负担,严重影响患者的生活质量。因此,迫切需要一种不给患者带来沉重负担的新型治疗策略。因此,我们评估了使用顺铂(一种用于治疗膀胱癌的常用抗癌药物)和慢病毒载体介导的基因转移的组合对膀胱癌细胞系的肿瘤生长抑制作用,其中载体已知具有最小的细胞毒性。方法将含有肿瘤抑制基因p53、p16和磷酸酶及紧张素同源性(PTEN)的慢病毒载体分别感染人膀胱癌细胞株UMUC3和T24,然后用CDDP治疗。结果p53、p16或PTEN基因的转导与CDDP对膀胱癌细胞的抗肿瘤作用相当。此外,慢病毒载体介导的肿瘤抑制基因转导与CDDP结合,相对于单独使用载体或CDDP的个体治疗策略,显示出更好的抗肿瘤效果。结论慢病毒载体介导的基因转导是治疗膀胱癌的一种有希望的替代方法。目前以cddp为基础的化疗方案可能在未来被取代。此外,基因治疗与化疗相结合可能是治疗膀胱癌的有效方法。
{"title":"Lentiviral vector-mediated gene transfer combined with cisplatin enhances tumor suppression in human bladder cancer cell lines","authors":"Misa Ichikawa ,&nbsp;Wataru Matsunaga ,&nbsp;Takahiro Ishikawa ,&nbsp;Akinobu Gotoh","doi":"10.1016/j.pmu.2019.06.002","DOIUrl":"10.1016/j.pmu.2019.06.002","url":null,"abstract":"<div><h3>Purpose</h3><p><span><span>Non-muscle invasive bladder cancer (NMIBC) shows high rates of recurrence and frequently progresses to more advanced stages, such as </span>muscle invasive bladder cancer (MIBC). Repetition of </span>treatment<span> and recurrence are serious burdens and cause severe reduction in the quality of life<span><span> (QOL) of patients. Thus, a novel therapeutic strategy without high burdens on the patients is an urgent requirement. Consequently, we evaluated tumor growth inhibition in bladder cancer cell lines using a combination of </span>cisplatin<span> (CDDP), one of the prevailing anticancer drugs to treat bladder cancer, and lentiviral vector-mediated gene transfer, where the vector is known to have minimal cytotoxicity.</span></span></span></p></div><div><h3>Methods</h3><p><span>Lentiviral vector with tumor suppressor genes including </span><em>p53</em>, <span><em>p16</em></span><span><span>, and phosphatase and </span>tensin homology (</span><em>PTEN</em>) were infected to human bladder cancer cell lines, UMUC3 and T24, followed by CDDP treatment.</p></div><div><h3>Results</h3><p>The transduction of the <em>p53</em>, <em>p16</em>, or <em>PTEN</em> gene was equivalent to the antitumor efficacy of CDDP against bladder cancer cells. Furthermore, lentiviral vector-mediated transduction of tumor suppressive genes in combination with CDDP showed superior antitumor effects relative to individual treatment strategies with the vector or CDDP alone.</p></div><div><h3>Conclusion</h3><p>Lentiviral vector-mediated gene transduction is a promising alternative to the existing therapy in treating bladder cancer. The current protocol of CDDP-based chemotherapy may be replaced in the future. Moreover, the combination of gene therapy and chemotherapy may be an effective treatment for bladder cancer.</p></div>","PeriodicalId":101009,"journal":{"name":"Personalized Medicine Universe","volume":"8 ","pages":"Pages 15-19"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pmu.2019.06.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79716595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Lentiviral vector-mediated transfection of p53, p16 and PTEN genes against human renal cell carcinoma cell lines 慢病毒载体介导的p53、p16和PTEN基因对人肾细胞癌细胞系的转染
Pub Date : 2019-07-01 DOI: 10.1016/j.pmu.2019.03.001
Wataru Matsunaga , Misa Ichikawa , Takahiro Ishikawa , Akinobu Gotoh

Purpose

Viral vector-mediated gene therapies for cancers have been eagerly studied in recent years. However, lentiviral vectors are not widely used despite their practical characteristics such as low cytotoxicity and prolonged expression of the transgenes. Renal cell carcinoma (RCC) is highly refractory to known cancer treatment drugs, and surgical resection is used as the most common treatment of RCC. Therefore, we thought that lentiviral vector-mediated gene therapy would become a promising strategy of the treatment of RCC. In this study, we examine the lentiviral vector-mediated transfection of tumor suppressor genes against RCC cell lines.

Methods

Lentiviral vectors that contained the tumor suppressor genes, p53, p16, and PTEN, were transfected into human RCC cell lines, RCC4/VHL, 786-O and ACHN.

Results

Significant growth inhibition was observed in RCC cells on transfection with the tumor suppression genes. Especially, transfection of p16 showed remarkable effect on all experimental cell lines.

Conclusions

The results of this study demonstrate that lentivirus-mediated transfection of tumor suppressor genes exerts promising anti-tumor effects on RCC cell lines.

目的近年来,病毒载体介导的癌症基因治疗得到了广泛的研究。然而,尽管慢病毒载体具有低细胞毒性和延长转基因表达时间等实用特性,但其应用并不广泛。肾细胞癌(RCC)对已知的癌症治疗药物具有高度难治性,手术切除是RCC最常用的治疗方法。因此,我们认为慢病毒载体介导的基因治疗将成为治疗RCC的一种有前景的策略。在这项研究中,我们研究了慢病毒载体介导的肿瘤抑制基因对RCC细胞系的转染。方法将含有肿瘤抑制基因p53、p16和PTEN的慢病毒载体转染人RCC细胞系、RCC4/VHL、786-O和ACHN。结果转染抑癌基因后,RCC细胞生长受到明显抑制。特别是p16转染对所有实验细胞系均有显著影响。结论慢病毒介导的肿瘤抑制基因转染对RCC细胞株具有良好的抗肿瘤作用。
{"title":"Lentiviral vector-mediated transfection of p53, p16 and PTEN genes against human renal cell carcinoma cell lines","authors":"Wataru Matsunaga ,&nbsp;Misa Ichikawa ,&nbsp;Takahiro Ishikawa ,&nbsp;Akinobu Gotoh","doi":"10.1016/j.pmu.2019.03.001","DOIUrl":"https://doi.org/10.1016/j.pmu.2019.03.001","url":null,"abstract":"<div><h3>Purpose</h3><p><span><span>Viral vector-mediated gene therapies for cancers have been eagerly studied in recent years. However, lentiviral vectors are not widely used despite their practical characteristics such as low cytotoxicity and prolonged expression of the transgenes. </span>Renal cell carcinoma<span> (RCC) is highly refractory to known cancer treatment </span></span>drugs<span>, and surgical resection is used as the most common treatment of RCC. Therefore, we thought that lentiviral vector-mediated gene therapy would become a promising strategy of the treatment of RCC. In this study, we examine the lentiviral vector-mediated transfection of tumor suppressor genes<span> against RCC cell lines.</span></span></p></div><div><h3>Methods</h3><p>Lentiviral vectors that contained the tumor suppressor genes, <span><em>p53, </em><em>p16</em><em>,</em></span> and <em>PTEN,</em> were transfected into human RCC cell lines, RCC4/VHL, 786-O and ACHN.</p></div><div><h3>Results</h3><p>Significant growth inhibition was observed in RCC cells on transfection with the tumor suppression genes. Especially, transfection of <em>p16</em> showed remarkable effect on all experimental cell lines.</p></div><div><h3>Conclusions</h3><p>The results of this study demonstrate that lentivirus-mediated transfection of tumor suppressor genes exerts promising anti-tumor effects on RCC cell lines.</p></div>","PeriodicalId":101009,"journal":{"name":"Personalized Medicine Universe","volume":"8 ","pages":"Pages 10-14"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pmu.2019.03.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91633575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
CTCs as tumor antigens: A pilot study using ex-vivo expanded tumor cells to be used as lysate for DC vaccines ctc作为肿瘤抗原:一项利用体外扩增肿瘤细胞作为DC疫苗裂解物的初步研究
Pub Date : 2019-07-01 DOI: 10.1016/j.pmu.2019.05.001
Ayaka Nakamura , Minako Abe , Yasuha Ono , Yukie Saeki , Fumika Kono , Hazuki Sakuma , Ayumi Morokuma , Yoshimori Ishihara , Hiroyuki Abe

The global incidence and mortality rates of colorectal cancer is rising, and has surpassed lung cancer as the highest incidence of all types of cancers in Japan [1]. Standard treatments include surgery and chemotherapy, however immunotherapy using Dendritic Cell (DC) vaccines is also recognized as an effective treatment for many cancers including colorectal cancer. DCs are the most potent antigen presenting cells, which activate CD 4+/CD8+ T cells and induce cytotoxic T lymphocytes (CTLs) to attack cancer cells. Tumor antigens used in DC vaccines are typically defined tumor-derived peptides, however, using autologous tumor lysates produces significantly higher response rates [2]. It is not always feasible to obtain fresh whole tumor to use as lysate, and particularly in the case of colorectal cancer, it is difficult to collect an aseptic specimen for use. We therefore explored the possibility of producing lysate from circulating tumor cells (CTCs) that can be collected aseptically from peripheral blood. We created a model of capturing live CTCs from a colorectal cancer cell line, culturing and expanding these cells, and creating lysate from these cultured CTCs.

结直肠癌的全球发病率和死亡率正在上升,并已超过肺癌,成为日本所有类型癌症中发病率最高的癌症。标准的治疗方法包括手术和化疗,但是使用树突状细胞(DC)疫苗的免疫疗法也被认为是包括结直肠癌在内的许多癌症的有效治疗方法。树突状细胞是最有效的抗原提呈细胞,可激活cd4 +/CD8+ T细胞,诱导细胞毒性T淋巴细胞(ctl)攻击癌细胞。DC疫苗中使用的肿瘤抗原通常是确定的肿瘤来源的肽,然而,使用自体肿瘤裂解物产生明显更高的反应率bb0。获得新鲜的整个肿瘤用作裂解物并不总是可行的,特别是在结直肠癌的情况下,很难收集无菌标本供使用。因此,我们探索了从循环肿瘤细胞(ctc)中生产裂解物的可能性,这种裂解物可以从外周血中无菌收集。我们创建了一个模型,从结直肠癌细胞系中捕获活的ctc,培养和扩增这些细胞,并从这些培养的ctc中产生裂解物。
{"title":"CTCs as tumor antigens: A pilot study using ex-vivo expanded tumor cells to be used as lysate for DC vaccines","authors":"Ayaka Nakamura ,&nbsp;Minako Abe ,&nbsp;Yasuha Ono ,&nbsp;Yukie Saeki ,&nbsp;Fumika Kono ,&nbsp;Hazuki Sakuma ,&nbsp;Ayumi Morokuma ,&nbsp;Yoshimori Ishihara ,&nbsp;Hiroyuki Abe","doi":"10.1016/j.pmu.2019.05.001","DOIUrl":"10.1016/j.pmu.2019.05.001","url":null,"abstract":"<div><p><span><span><span>The global incidence and mortality rates of colorectal cancer is rising, and has surpassed lung cancer as the highest incidence of all types of cancers in Japan [1]. Standard treatments include surgery and chemotherapy, however </span>immunotherapy using Dendritic Cell (DC) vaccines is also recognized as an effective treatment for many cancers including colorectal cancer. DCs are the most potent </span>antigen presenting cells<span>, which activate CD 4+/CD8+ T cells and induce cytotoxic T lymphocytes (CTLs) to attack cancer cells<span>. Tumor antigens used in DC vaccines are typically defined tumor-derived peptides, however, using autologous tumor lysates produces significantly higher response rates </span></span></span><span>[2]</span><span>. It is not always feasible to obtain fresh whole tumor to use as lysate, and particularly in the case of colorectal cancer, it is difficult to collect an aseptic specimen for use. We therefore explored the possibility of producing lysate from circulating tumor cells<span> (CTCs) that can be collected aseptically from peripheral blood. We created a model of capturing live CTCs from a colorectal cancer cell line, culturing and expanding these cells, and creating lysate from these cultured CTCs.</span></span></p></div>","PeriodicalId":101009,"journal":{"name":"Personalized Medicine Universe","volume":"8 ","pages":"Pages 27-31"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pmu.2019.05.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83883892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Investigation of diffusion, practical use, and utility of a medical device for Japanese hemophilia patients in a single institution 一种日本血友病患者医疗器械在单一机构的扩散、实际使用和效用调查
Pub Date : 2019-07-01 DOI: 10.1016/j.pmu.2019.05.003
Reiko Iriuchijima , Kimiaki Suzuki , Azusa Nagao , Takashi Suzuki , Yoshihisa Okamoto , Tomohide Akase , Takanori Seki

Introduction

Standardized treatments are intended to eliminate bias by each hospital and physician and provide unified and appropriate treatment. Personalized treatments clarify the pathological condition of each patient and provide treatment without any surplus or deficiency based on standardized treatments. In this study, we take the example of hemophilia, one of the rare diseases, and measure diffusion, practical use, and utility of medical devices at the clinical site, the drug cost and clinical outcome, demonstrate its usefulness, and present measures to introduce standardized and individualized treatment. myPKFiT® is a medical device that allows authorized users to simulate dosing regimens with Hemophilia patients' pharmacokinetic profiles of FVIII based on 2 blood samples.

Methods

We interviewed clinical psychologists, nurses, and physicians focusing on “improvement of awareness” and “removal of disability”, collecting clinical data, annualized bleeding rate (ABR), annualized joint bleeding rate (AJBR), and cost of FVIII consumption in Ogikubo Hospital, Hemophilia center.

Results

We specified the original method of Ogikubo Hospital from the results of interview on adopting medical devices. Clinical outcome analysis was performed on patients with medical devices who have transfusion records before and after an operation.

Conclusion

Though personalized treatment can be formalized to some extent, it is expected that medical treatment skills and management by tacit knowledge are affected in individualized treatment based on standardized treatment. Medical institutions and medical staff are the main body sharing and deploying measures to disseminate and utilize medical devices, cooperating with them can be an effective management of standardized and individualized treatment.

标准化治疗旨在消除每家医院和医生的偏见,提供统一和适当的治疗。个性化治疗明确了每个患者的病理情况,在标准化治疗的基础上提供治疗,没有多余或不足。本研究以血友病这一罕见疾病为例,对医疗器械在临床现场的扩散、实际使用、效用、药物成本和临床效果进行测量,论证其有效性,并提出引入规范化和个体化治疗的措施。myPKFiT®是一种医疗设备,允许授权用户基于2份血液样本模拟血友病患者FVIII药代动力学特征的给药方案。方法对大久保医院血友病中心的临床心理学家、护士和医生就“提高意识”和“消除残疾”进行访谈,收集临床数据、年化出血率(ABR)、年化关节出血率(AJBR)和FVIII消费成本。结果从访谈结果中明确了大久保医院采用医疗器械的原始方法。对手术前后有输血记录的医疗器械患者进行临床结果分析。结论个性化治疗虽能在一定程度上正规化,但在规范化治疗的基础上,个性化治疗对医疗技能和隐性知识管理有一定影响。医疗机构和医务人员是医疗器械传播利用措施共享和部署的主体,与医疗机构和医务人员合作,才能有效管理医疗器械的规范化、个体化治疗。
{"title":"Investigation of diffusion, practical use, and utility of a medical device for Japanese hemophilia patients in a single institution","authors":"Reiko Iriuchijima ,&nbsp;Kimiaki Suzuki ,&nbsp;Azusa Nagao ,&nbsp;Takashi Suzuki ,&nbsp;Yoshihisa Okamoto ,&nbsp;Tomohide Akase ,&nbsp;Takanori Seki","doi":"10.1016/j.pmu.2019.05.003","DOIUrl":"10.1016/j.pmu.2019.05.003","url":null,"abstract":"<div><h3>Introduction</h3><p><span><span>Standardized treatments are intended to eliminate bias by each hospital and physician and provide unified and appropriate treatment. Personalized treatments clarify the pathological condition of each patient and provide treatment without any surplus or deficiency based on standardized treatments. In this study, we take the example of </span>hemophilia<span>, one of the rare diseases, and measure diffusion, practical use, and utility of medical devices at the clinical site, the drug cost and clinical outcome, demonstrate its usefulness, and present measures to introduce standardized and individualized treatment. myPKFiT® is a medical device that allows authorized users to simulate dosing regimens with Hemophilia patients' </span></span>pharmacokinetic profiles of FVIII based on 2 blood samples.</p></div><div><h3>Methods</h3><p>We interviewed clinical psychologists, nurses, and physicians focusing on “improvement of awareness” and “removal of disability”, collecting clinical data, annualized bleeding rate (ABR), annualized joint bleeding rate (AJBR), and cost of FVIII consumption in Ogikubo Hospital, Hemophilia center.</p></div><div><h3>Results</h3><p>We specified the original method of Ogikubo Hospital from the results of interview on adopting medical devices. Clinical outcome analysis was performed on patients with medical devices who have transfusion records before and after an operation.</p></div><div><h3>Conclusion</h3><p>Though personalized treatment can be formalized to some extent, it is expected that medical treatment skills and management by tacit knowledge are affected in individualized treatment based on standardized treatment. Medical institutions and medical staff are the main body sharing and deploying measures to disseminate and utilize medical devices, cooperating with them can be an effective management of standardized and individualized treatment.</p></div>","PeriodicalId":101009,"journal":{"name":"Personalized Medicine Universe","volume":"8 ","pages":"Pages 32-37"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pmu.2019.05.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75802646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Effect of oral consumption of Panax ginseng aqueous extract on natural killer cell cytotoxicity in humans 口服人参水提物对人体自然杀伤细胞毒性的影响
Pub Date : 2019-07-01 DOI: 10.1016/j.pmu.2018.09.001
Kazuyoshi Takeda , Ko Okumura

Purpose

Panax ginseng (P. ginseng) root is a complementary and alternative medicine (CAM) typically used in traditional Asian medicine. We have reported that oral consumption of the P. ginseng aqueous extract (PgE) by mice augments natural killer (NK) cell activity, which is critical for immune surveillance against tumors. In this study, we further examined the effect of oral consumption of PgE on human NK cell phenotypes and cytotoxicity.

Methods

Here we examined the effects of oral intake of PgE (1000 mg per day, as recommended by the manufacturer) for two weeks on NK cell activity in ten human volunteers in a cross-over trial.

Results

No adverse reactions were observed in any volunteers, although two dropped out due to personal reasons. Oral intake of 1000 mg of PgE for two weeks did not affect the size of the NK cell population or CD56 expression on NK cells. However, NK cell cytotoxicity was significantly augmented in five out of eight subjects. When the NK cell response was divided into two categories (significantly increased or stable/decreased), Fisher's exact test and the χ2 test demonstrated a significant difference in NK cell cytotoxicity between the PgE-treated and placebo groups.

Conclusion

Oral intake of 1000 mg of PgE for two weeks significantly augmented NK cell cytotoxicity over that observed with the placebo.

目的:人参根是亚洲传统医学中常用的一种补充和替代药物。我们已经报道了口服人参水提取物(PgE)小鼠增加自然杀伤(NK)细胞活性,这是对肿瘤的免疫监视至关重要。在这项研究中,我们进一步研究了口服PgE对人类NK细胞表型和细胞毒性的影响。在交叉试验中,我们研究了口服PgE(按照制造商的建议,每天1000毫克)两周对10名人类志愿者NK细胞活性的影响。结果2名志愿者因个人原因退出,无不良反应发生。口服1000 mg PgE两周不影响NK细胞群的大小或NK细胞上CD56的表达。然而,NK细胞毒性在8名受试者中有5名显著增强。当NK细胞反应分为两类(显著增加或稳定/降低)时,Fisher精确检验和χ2检验显示pge治疗组和安慰剂组之间NK细胞毒性有显著差异。结论与安慰剂组相比,口服PgE 1000 mg 2周可显著增强NK细胞毒性。
{"title":"Effect of oral consumption of Panax ginseng aqueous extract on natural killer cell cytotoxicity in humans","authors":"Kazuyoshi Takeda ,&nbsp;Ko Okumura","doi":"10.1016/j.pmu.2018.09.001","DOIUrl":"10.1016/j.pmu.2018.09.001","url":null,"abstract":"<div><h3>Purpose</h3><p><span><em>Panax </em><em>ginseng</em></span> (<em>P. ginseng</em><span>) root is a complementary and alternative medicine (CAM) typically used in traditional Asian medicine. We have reported that oral consumption of the </span><em>P. ginseng</em> aqueous extract (<em>Pg</em><span>E) by mice augments natural killer (NK) cell activity, which is critical for immune surveillance against tumors. In this study, we further examined the effect of oral consumption of </span><em>Pg</em>E on human NK cell phenotypes and cytotoxicity.</p></div><div><h3>Methods</h3><p>Here we examined the effects of oral intake of <em>Pg</em>E (1000 mg per day, as recommended by the manufacturer) for two weeks on NK cell activity in ten human volunteers in a cross-over trial.</p></div><div><h3>Results</h3><p>No adverse reactions were observed in any volunteers, although two dropped out due to personal reasons. Oral intake of 1000 mg of <em>Pg</em><span>E for two weeks did not affect the size of the NK cell population or CD56 expression on NK cells. However, NK cell cytotoxicity was significantly augmented in five out of eight subjects. When the NK cell response<span> was divided into two categories (significantly increased or stable/decreased), Fisher's exact test and the χ</span></span><sup>2</sup> test demonstrated a significant difference in NK cell cytotoxicity between the <em>Pg</em>E-treated and placebo groups.</p></div><div><h3>Conclusion</h3><p>Oral intake of 1000 mg of <em>Pg</em>E for two weeks significantly augmented NK cell cytotoxicity over that observed with the placebo.</p></div>","PeriodicalId":101009,"journal":{"name":"Personalized Medicine Universe","volume":"8 ","pages":"Pages 20-26"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pmu.2018.09.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77037020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Lentiviral vector-mediated transfection of p53, p16 and PTEN genes against human renal cell carcinoma cell lines 慢病毒载体介导的p53、p16和PTEN基因对人肾细胞癌细胞系的转染
Pub Date : 2019-07-01 DOI: 10.1016/J.PMU.2019.03.001
Wataru Matsunaga, Misa Ichikawa, T. Ishikawa, A. Gotoh
{"title":"Lentiviral vector-mediated transfection of p53, p16 and PTEN genes against human renal cell carcinoma cell lines","authors":"Wataru Matsunaga, Misa Ichikawa, T. Ishikawa, A. Gotoh","doi":"10.1016/J.PMU.2019.03.001","DOIUrl":"https://doi.org/10.1016/J.PMU.2019.03.001","url":null,"abstract":"","PeriodicalId":101009,"journal":{"name":"Personalized Medicine Universe","volume":"IA-21 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84607668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
A proposed simple screening method to determine relative contributions of CYP3A4 and CYP3A5 to drug metabolism in vitro 提出了一种简单的筛选方法来确定CYP3A4和CYP3A5对体外药物代谢的相对贡献
Pub Date : 2019-07-01 DOI: 10.1016/j.pmu.2019.04.001
Jun Matsumoto , Hiroyoshi Nakamura , Su Nwe San , Hikari Sato , Manami Takezawa , Ryuto Kishi , Yutaro Kito , Junko Sugano , Mai Izuki , Nao Yanagisawa , Naoki Ikeda , Yusuke Saito , Yoshinori Kato , Harumi Yamada , Masachika Fujiyoshi , Noritaka Ariyoshi

Purpose

The cytochrome P450 (CYP) 3A family of enzymes metabolize the majority of clinically used drugs. CYP3A4 and CYP3A5 are the two major CYP3A isoforms, but exhinbit different substrate specificity. The aim of this study was to establish a simple screening method to determine the relative contributions of CYP3A4 and CYP3A5 to drug metabolism in vitro.

Methods

A screening method was developed based on competitive inhibition using luciferin-PPXE (L-PPXE), a luminogenic CYP3A substrate. CYP3cide, tacrolimus, and midazolam were selected as standard compounds metabolized by CYP3A4 or CYP3A5. Nine clinically-used drugs were evaluated for their abilities to inhibit luminescence resulting from L-PPXE metabolism. Appropriate reaction conditions for the screening method were determined using recombinant CYP3A4 and CYP3A5.

Results

A significant decrease in luminescence resulting from L-PPXE metabolism by CYP3A4 and CYP3A5 was observed only for drugs reported to be metabolized by CYP3As. The substrate specificities of CYP3A4 or CYP3A5 for the proposed CYP3A substrates using our screening method were consistent with those of previous reports or available drug information from pharmaceutical companies. The reaction volume for this method was 50 μL, and the time required for the entire procedure was 70 min. Furthermore, this screening can be performed using a single tube with minimal training.

Conclusions

Through the establishment of our screening method in the present study, we are sure it is useful to determine the relative contributions of CYP3A4 and CYP3A5 to drug metabolism in vitro.

目的细胞色素P450 (CYP) 3A家族酶代谢大多数临床使用的药物。CYP3A4和CYP3A5是CYP3A的两种主要亚型,但表现出不同的底物特异性。本研究的目的是建立一种简单的筛选方法来确定CYP3A4和CYP3A5在体外药物代谢中的相对贡献。方法采用致光CYP3A底物luciferin-PPXE (L-PPXE)竞争性抑制筛选方法。选择cyp3ide、他克莫司和咪达唑仑作为CYP3A4或CYP3A5代谢的标准化合物。我们评估了9种临床使用的药物对L-PPXE代谢引起的发光的抑制能力。以重组CYP3A4和CYP3A5确定筛选方法的适宜反应条件。结果CYP3A4和CYP3A5代谢L-PPXE导致的发光明显下降仅在被CYP3As代谢的药物中观察到。使用我们的筛选方法,CYP3A4或CYP3A5对CYP3A底物的底物特异性与先前的报道或制药公司的现有药物信息一致。该方法的反应体积为50 μL,整个过程所需时间为70 min。此外,该筛选方法可以使用单管进行,仅需最少的训练。结论通过本研究建立的筛选方法,可以确定CYP3A4和CYP3A5对体外药物代谢的相对贡献。
{"title":"A proposed simple screening method to determine relative contributions of CYP3A4 and CYP3A5 to drug metabolism in vitro","authors":"Jun Matsumoto ,&nbsp;Hiroyoshi Nakamura ,&nbsp;Su Nwe San ,&nbsp;Hikari Sato ,&nbsp;Manami Takezawa ,&nbsp;Ryuto Kishi ,&nbsp;Yutaro Kito ,&nbsp;Junko Sugano ,&nbsp;Mai Izuki ,&nbsp;Nao Yanagisawa ,&nbsp;Naoki Ikeda ,&nbsp;Yusuke Saito ,&nbsp;Yoshinori Kato ,&nbsp;Harumi Yamada ,&nbsp;Masachika Fujiyoshi ,&nbsp;Noritaka Ariyoshi","doi":"10.1016/j.pmu.2019.04.001","DOIUrl":"10.1016/j.pmu.2019.04.001","url":null,"abstract":"<div><h3>Purpose</h3><p><span>The cytochrome P450 (CYP) 3A family of enzymes metabolize the majority of clinically used drugs<span><span>. CYP3A4 and </span>CYP3A5<span> are the two major CYP3A isoforms, but exhinbit different substrate specificity. The aim of this study was to establish a simple screening method to determine the relative contributions of CYP3A4 and CYP3A5 to drug metabolism </span></span></span><em>in vitro</em>.</p></div><div><h3>Methods</h3><p>A screening method was developed based on competitive inhibition using luciferin-PPXE (L-PPXE), a luminogenic CYP3A substrate. CYP3cide, tacrolimus, and midazolam were selected as standard compounds metabolized by CYP3A4 or CYP3A5. Nine clinically-used drugs were evaluated for their abilities to inhibit luminescence resulting from L-PPXE metabolism. Appropriate reaction conditions for the screening method were determined using recombinant CYP3A4 and CYP3A5.</p></div><div><h3>Results</h3><p>A significant decrease in luminescence resulting from L-PPXE metabolism by CYP3A4 and CYP3A5 was observed only for drugs reported to be metabolized by CYP3As. The substrate specificities of CYP3A4 or CYP3A5 for the proposed CYP3A substrates using our screening method were consistent with those of previous reports or available drug information from pharmaceutical companies. The reaction volume for this method was 50 μL, and the time required for the entire procedure was 70 min. Furthermore, this screening can be performed using a single tube with minimal training.</p></div><div><h3>Conclusions</h3><p>Through the establishment of our screening method in the present study, we are sure it is useful to determine the relative contributions of CYP3A4 and CYP3A5 to drug metabolism <em>in vitro</em>.</p></div>","PeriodicalId":101009,"journal":{"name":"Personalized Medicine Universe","volume":"8 ","pages":"Pages 41-44"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pmu.2019.04.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78485436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Changes of blood myokine levels following human skeletal muscle contraction using belt electrode skeletal muscle electrical stimulation 带电极骨骼肌电刺激下人体骨骼肌收缩后血液肌因子水平的变化
Pub Date : 2019-07-01 DOI: 10.1016/j.pmu.2019.03.002
Kouki Tomida , Hajime Nakae

Interleukin (IL)-6 is a myokine secreted from skeletal muscle fibers by the stimulation of muscle contraction. IL-6 then acts on skeletal muscle itself or on remote organs through the blood circulation, resulting in various health benefits.

The quantity of mobilized muscle, exercise intensity, and exercise time are deeply involved in the rise of blood IL-6 levels. In this study, we investigated whether high sensitivity C-reactive protein, IL-6, and the anti-inflammatory cytokine, IL-10, were produced in humans by muscle contraction due to electrical stimulation. Six healthy men underwent 20 min of belt electrode skeletal muscle electrical stimulation. No time-dependent changes in IL-6, IL-10, and high sensitivity C-reactive protein were observed. These results suggest that blood myokines do not increase in response to standard electrical stimulation.

白细胞介素(IL)-6是骨骼肌纤维通过刺激肌肉收缩分泌的一种肌因子。然后,IL-6通过血液循环作用于骨骼肌本身或远处的器官,从而产生各种健康益处。运动肌肉量、运动强度和运动时间与血液IL-6水平升高密切相关。在这项研究中,我们研究了高敏感性c反应蛋白IL-6和抗炎细胞因子IL-10是否通过电刺激引起的肌肉收缩在人体中产生。6名健康男性接受带电极骨骼肌电刺激20分钟。IL-6、IL-10和高敏c反应蛋白无时间依赖性变化。这些结果表明,血液肌因子在标准电刺激下不会增加。
{"title":"Changes of blood myokine levels following human skeletal muscle contraction using belt electrode skeletal muscle electrical stimulation","authors":"Kouki Tomida ,&nbsp;Hajime Nakae","doi":"10.1016/j.pmu.2019.03.002","DOIUrl":"10.1016/j.pmu.2019.03.002","url":null,"abstract":"<div><p>Interleukin (IL)-6 is a myokine secreted from skeletal muscle fibers by the stimulation of muscle contraction. IL-6 then acts on skeletal muscle itself or on remote organs through the blood circulation, resulting in various health benefits.</p><p>The quantity of mobilized muscle, exercise intensity, and exercise time are deeply involved in the rise of blood IL-6 levels. In this study, we investigated whether high sensitivity C-reactive protein, IL-6, and the anti-inflammatory cytokine, IL-10, were produced in humans by muscle contraction due to electrical stimulation. Six healthy men underwent 20 min of belt electrode skeletal muscle electrical stimulation. No time-dependent changes in IL-6, IL-10, and high sensitivity C-reactive protein were observed. These results suggest that blood myokines do not increase in response to standard electrical stimulation.</p></div>","PeriodicalId":101009,"journal":{"name":"Personalized Medicine Universe","volume":"8 ","pages":"Pages 45-47"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pmu.2019.03.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83392522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
期刊
Personalized Medicine Universe
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1